

List of approved Form-IV intimation regarding discontinuation of scheduled formulations for the Financial Year 2022-2023 (As on 31.03.2023)

Sl.	Company Name	Date of application	Brand name	Composition	Reason for discontinuation	Date of final direction given to company by NPPA	To continue production / import and sale up to	Public Notice Issuance date
1	M/s Indoco Remedies Limited, Mumbai	15.03.2022 (e-mail)	Clamchek 625 Tablets	Amoxycillin (500mg) and Clavulanic acid (125 mg)	Decreasing sales and low value	19.09.2022	02.09.2022	02.03.2022
2	M/s Indoco Remedies Limited, Mumbai	15.03.2022 (e-mail)	AXL 500mg Capsules	Amoxycillin (500mg)	Decreasing sales and low value	19.09.2022	02.09.2022	02.03.2022
3	M/s Indoco Remedies Limited, Mumbai	15.03.2022 (e-mail)	OH-D3 Capsules	Vitamin D3 (Cholecalciferol) 60000IU	Decreasing sales and low value	19.09.2022	02.09.2022	02.03.2022
4	M/s Kedrion Biopharma India Private Limited, New Delhi	17.05.2022	RhoGAM®	Human Anti-D Immunoglobulin 300mcg	Decision of Stakeholders to discontinue the business in India	06.10.2022	05.10.2023	16.05.2022
5	M/s Kedrion Biopharma India Private Limited, New Delhi	17.05.2022	EMOCLOT	Human Plasma Coagulation factor VIII	Decision of Stakeholders to discontinue the business in India	06.10.2022	05.10.2023	16.05.2022
6	M/s Kedrion Biopharma India Private Limited, New Delhi	17.05.2022	IMMUNORHO	Human Anti-D Immunoglobulin 300mcg/vial	Decision of Stakeholders to discontinue the business in India	06.10.2022	05.10.2023	16.05.2022
7	M/s Kedrion Biopharma India Private Limited, New Delhi	17.05.2022	IMMUHBs	Human Hepatitis B Immunoglobulin	Decision of Stakeholders to discontinue the business in India	06.10.2022	05.10.2023	16.05.2022
8	M/s Kedrion Biopharma India Private Limited, New Delhi	17.05.2022	TETANUS GAMMA	Human Tetanus Immunoglobulin	Decision of Stakeholders to discontinue the business in India	06.10.2022	05.10.2023	16.05.2022
9	M/s Kedrion Biopharma India Private Limited, New Delhi	17.05.2022	AIMAFIX	Human Plasma Coagulation factor IX	Decision of Stakeholders to discontinue the business in India	06.10.2022	05.10.2023	16.05.2022

10	M/s Unison Pharmaceutical Pvt. Ltd., Gujarat	22.07.2022 (e-mail)	L-OSON 250	Levofloxacin 250mg Tablet	Low market share and lack of demand	19.09.2022	31.01.2023	21.07.2022
11	M/s Unison Pharmaceutical Pvt. Ltd., Gujarat	22.07.2022 (e-mail)	L-OSON 500	Levofloxacin 500mg Tablet	Low market share and lack of demand	19.09.2022	31.01.2023	21.07.2022
12	M/s Unison Pharmaceutical Pvt. Ltd., Gujarat	22.07.2022 (e-mail)	ODANSON Tablet	Ondansetrone 4mg Tablet	Low market share and lack of demand	19.09.2022	31.01.2023	21.07.2022
13	M/s Unison Pharmaceutical Pvt. Ltd., Gujarat	01.10.2022 (e-mail)	XYLOSON ADULT 0.1 % NASAL DROPS 10 ML	Xylometazoline HCL IP 0.05% w/v Nasal Solution	Low market share and lack of demand	25.10.2022	31.03.2023	28.09.2022
14	M/s Unison Pharmaceutical Pvt. Ltd., Gujarat	01.10.2022 (e-mail)	XYLOSON PEDIATRIC 0.05 % NASAL DROPS 10 ML	Xylometazoline HCL IP 0.1% w/v Nasal Solution	Low market share and lack of demand	25.10.2022	31.03.2023	28.09.2022
15	M/s Neon Laboratories Limited, Mumbai	07.10.2022	ERYTRUST 2000 IU INJECTION	Erythropoietin concentrated solution I.P 2000 IU (Inj/PFS)	Insignificant Market share	11.01.2023	04.04.2023	05.10.2022
16	M/s Neon Laboratories Limited, Mumbai	07.10.2022	TIMOSIGHT 0.5 % EYE DROPS	Timolol Maleate I.P 0.5% w/v	Insignificant Market share	11.01.2023	04.04.2023	05.10.2022
17	M/s Baxter Pharmaceuticals India Pvt. Ltd., Gujarat	27.10.2022	SEDOZ 1mg INJECTION	Midazolam Injection 1mg/ml in 10 ml	Financially unviable to sustain production-continued Financial losses in the Indian Operations due to High cost	11.01.2023	19.04.2023	18.10.2022
18	M/s Baxter Pharmaceuticals India Pvt. Ltd., Gujarat	27.10.2022	SEDOZ 1mg INJECTION	Midazolam Injection 1mg/ml in 5 ml	Financially unviable to sustain production-continued Financial losses in the Indian Operations due to High cost	11.01.2023	19.04.2023	18.10.2022
19	M/s Baxter Pharmaceuticals India Pvt. Ltd., Gujarat	27.10.2022	SUCROFER 20mg INJECTION	Iron Sucrose Injection 20 mg/ml in 10 ml	Financially unviable to sustain production-continued Financial losses in the Indian Operations due to High cost	11.01.2023	19.04.2023	18.10.2022
20	M/s Baxter Pharmaceuticals India Pvt. Ltd., Gujarat	27.10.2022	SUCROFER 20mg INJECTION	Iron Sucrose Injection 20 mg/ml in 5 ml	Financially unviable to sustain production-continued Financial losses in the Indian Operations due to High cost	11.01.2023	19.04.2023	18.10.2022
21	M/s Baxter Pharmaceuticals India Pvt. Ltd., Gujarat	27.10.2022	ZEPITA	Piperacillin & Tazobactam Injection IP, 2.25 gm	Financially unviable to sustain production-continued Financial losses in the Indian Operations due to High cost	11.01.2023	19.04.2023	18.10.2022

22	M/s Baxter Pharmaceuticals India Pvt. Ltd., Gujarat	27.10.2022	ZEPITA 4000/500	Piperacillin & Tazobactam Injection IP 4.5 gm	Financially unviable to sustain production-continued Financial losses in the Indian Operations due to High cost	11.01.2023	19.04.2023	18.10.2022
23	M/s Baxter Pharmaceuticals India Pvt. Ltd., Gujarat	27.10.2022	PANISA	Pantoprazole for Injection 40 mg	Financially unviable to sustain production-continued Financial losses in the Indian Operations due to High cost	11.01.2023	19.04.2023	18.10.2022
24	M/s Baxter Pharmaceuticals India Pvt. Ltd., Gujarat	27.10.2022	PROFOL 10 mg	Propofol Injection IP 10 mg/ml in 10 ml	Financially unviable to sustain production-continued Financial losses in the Indian Operations due to High cost	11.01.2023	19.04.2023	18.10.2022
25	M/s Baxter Pharmaceuticals India Pvt. Ltd., Gujarat	27.10.2022	PROFOL 10 mg	Propofol Injection IP 10 mg/ml in 20 ml	Financially unviable to sustain production-continued Financial losses in the Indian Operations due to High cost	11.01.2023	19.04.2023	18.10.2022
26	M/s Baxter Pharmaceuticals India Pvt. Ltd., Gujarat	27.10.2022	PROFOL 10 mg	Propofol Injection IP 10 mg/ml in 50 ml	Financially unviable to sustain production-continued Financial losses in the Indian Operations due to High cost	11.01.2023	19.04.2023	18.10.2022
27	M/s Pfizer Products India Pvt.Ltd., Mumbai	30.11.2022	CYKLOKAPRON 100MG	Tranexamic acid solution 100mg/ml	Insignificant market share	11.01.2023	31.05.2023	30.11.2022